Human Genome adopts 'poison pill' measure

LONDON (Reuters) - GlaxoSmithKline said it wou

(Reuters) - A Maryland judge denied

By Rocco Verducci:BMO recently downgraded Human Genome Sciences (HGSI) to Market Perform. This was based on the firm's belief that the risk of GlaxoSmithKline (GSK) rescinding its offer has increased and the likelihood of a significant price increase as a result of darapladib has been reduced. The firm lowered its price target to $13 from $17.

Human Genome Sciences has adopted a shareholder rights plan to fend off a $2.59 billion takeover offer from the British drug maker GlaxoSmithKline.

Human Genome Sciences adopted a shareholder rights plan with a 15% trigger in the wake of Glaxo's $2.6 billion hostile takeover bid for the biotech firm.

Cleaning products giant Clorox on Monday rejected buyout king Carl Icahn's unsolicited $12.6 billion takeover bid, saying it substantially undervalues the company.Clorox said its board unanimously agreed to turn back Icahn's offer, calling it "neither credible nor adequate."But it also adopted a new stockholder rights plan, a "poison pill" defense to protect shareholders in the case of a hostile raid on the company.

LONDON (Reuters) - GlaxoSmithKline said it would not proceed with its $2.6 billion offer for Human Genome Sciences unless the U.S.

(Reuters) - Netflix Inc has adopted a poison pill defense against a hostile takeover, it said on Monday, d